Regina The

Regina The

Auto-generated profile, based on publicly available information

Regina The

ZorgKeuzeLab, Delft, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
LLLaura van Lieshout
Laura van Lieshout
MGMalou E. Gelderblom
Malou E. Gelderblom
JHJoanne A. de Hullu
Joanne A. de Hullu
RTRegina The
Regina The
AGAlexandra A. van Ginkel
Alexandra A. van Ginkel
RHRosella P.M.G. Hermens
Rosella P.M.G. Hermens
The discovery of the fallopian tube epithelium as the origin of high-grade serous ovarian cancer has brought a new option for ovarian cancer prevention. The fallopian tubes have no known function after completion of childbearing and can be removed to reduce the lifetime risk of ovarian cancer. Although the lifetime risk in the general population does not justify preventive surgery in itself, salpingectomy can be performed during abdominal surgery for other indications, also known as an opportunistic salpingectomy. The popularity of opportunistic salpingectomy is increasing worldwide; however, the variation between gynecologists and hospitals in their advice on opportunistic salpingectomy occurs because of the remaining uncertainty of evidence. Therefore, whether a woman can make her own decision depends on the hospital or gynecologist she visits. We aimed to lower this practice variation by providing standardized and unbiased counseling material. We aimed to develop and test a patient decision aid for opportunistic salpingectomy in women undergoing pelvic gynecologic surgery to either retain the ovaries or opt for sterilization. We followed a systematic development process based on the International Patient Decision Aid Standards. Data were collected between June 2019 and June 2020, using both qualitative and quantitative methods. The development process that occurred in collaboration with patients and healthcare professionals was overseen by a multidisciplinary steering group and was divided into 4 phases: (1) assessment of decisional needs using individual telephone interviews and questionnaires; (2) development of content and format based on decisional needs, current literature, and guidelines; (3) alpha testing and the first revision round; and (4) alpha testing and the second revision round. An outline of the patient decision aid was developed on the basis of decisional needs, current literature, and guidelines. It became clear that the decision aid should consist of 2 separate paths: one with information specifically for salpingectomy in addition to abdominal surgery and one for salpingectomy as a sterilization method. Both paths contained information on the anatomy and function of ovaries and fallopian tubes, risk reduction of ovarian cancer, and potential benefits and risks of opportunistic salpingectomy. Moreover, the sterilization path contains information on various sterilization methods and risks of unwanted pregnancy. The patient decision aid was developed as an online tool that includes information chapters, a knowledge quiz, consideration statements, and a summary detailing the patient's preferences and considerations. Adjustments were made following alpha testing round 1. The improved patient decision aid was subjected to usability tests (alpha testing round 2), in which it scored an "excellent" in tests with patients and a "good" in tests with gynecologists. Furthermore, our patient decision aid met the requirements of 45 of 49 applicable items from the International Patient Decision Aid Standards criteria. In collaboration with patients and healthcare professionals, a patient decision aid was developed on opportunistic salpingectomy and salpingectomy as a sterilization method. Both patients and gynecologists believed it is a useful tool that supports patients in making an informed decision whether to undergo an opportunistic salpingectomy and supports the counseling process by gynecologists.

14 November 2022 in JMIR Cancer
Verified
Journal Article
Open access
JAJet W. Ankersmid
Jet W. Ankersmid
SSSabine Siesling
Sabine Siesling
LSLuc Strobbe
Luc Strobbe
JMJohanna M Meulepas
Johanna M Meulepas
YRYvonne E A van Riet
Yvonne E A van Riet
CDConstance H.C. Drossaert
Constance H.C. Drossaert
Background: Although the treatment for breast cancer is highly personalized, posttreatment surveillance remains one-size-fits-all: annual imaging and physical examination for at least five years after treatment. The INFLUENCE nomogram is a prognostic model for estimating the 5-year risk for locoregional recurrences and second primary tumors after breast cancer. The use of personalized outcome data (such as risks for recurrences) can enrich the process of shared decision-making (SDM) for personalized surveillance after breast cancer. Objective: This study aimed to develop a patient decision aid (PtDA), integrating personalized risk calculations on risks for recurrences, to support SDM for personalized surveillance after curative treatment for invasive breast cancer. Methods: For the development of the PtDA, the International Patient Decision Aids Standards development process was combined with a mixed methods design inspired by the development process of previously developed PtDAs. In the development, 8 steps were distinguished: establishing a multidisciplinary steering group; definition of the end users, scope, and purpose of the PtDA; assessment of the decisional needs of end users; defining requirements for the PtDA; determining the format and implementation strategy for the PtDA; prototyping; alpha testing; and beta testing. The composed steering group convened during regular working-group sessions throughout the development process. Results: The “Breast Cancer Surveillance Decision Aid” consists of 3 components that support the SDM process: a handout sheet on which personalized risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualized and which contains an explanation about the decision for surveillance and a login code for a web-based deliberation tool; a web-based deliberation tool, including a patient-reported outcome measure on fear of cancer recurrence; and a summary sheet summarizing patient preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Beta testing is currently ongoing. Conclusions: We developed an acceptable and usable PtDA that integrates personalized risk calculations for the risk for recurrences to support SDM for surveillance after breast cancer. The implementation and effects of the use of the “Breast Cancer Surveillance Decision Aid” are being investigated in a clinical trial.

29 April 2025 in Patient Education and Counseling
Verified
Journal Article
Open access
CBCato C. Bresser
Cato C. Bresser
HMHarm H.E. van Melick
Harm H.E. van Melick
RTRegina The
Regina The
PNPaul van der Nat
Paul van der Nat
MGMirjam M. Garvelink
Mirjam M. Garvelink
Patient decision aids (PtDAs) can support shared decision-making (SDM) by providing information about options, pros and cons and eliciting personal preferences. The aim of this study was to develop and test the acceptability and usability of a PtDA for patients with metastatic clear-cell renal cell carcinoma (RCC), the most common type of metastatic kidney cancer. User-centered mixed methods design. Co-creation process with stakeholders guided by the International Patient Decision Aids Standards (IPDAS) criteria, consisting of three main elements: (a) a needs assessment; (b) acceptability and usability testing; and (c) compatibility assessment with IPDAS criteria. Thirteen RCC patients and 29 healthcare professionals (HCP) participated in this study. Co-creation sessions were held with nine HCPs and a patient representative. Needs assessment (a) showed that patients lacked real treatment choices and wanted information on all treatment options, including life expectancy, side effects, psychological, and lifestyle advice. HCPs expect a PtDA to improve information delivery and patient engagement. A three-component PtDA was developed and tested (b), with positive feedback from both patients and professionals. The tool meets all 12 IPDAS criteria (c). The web-based PtDA was developed and adapted to address unmet needs and found to be acceptable and usable by patients and HCPs. The use of this tool could contribute to high quality, patient-centered and appropriate care for metastatic clear cell RCC patients in the Netherlands.

27 March 2022 in JMIR Preprints
Verified
Preprint
Open access
JAJet W. Ankersmid
Jet W. Ankersmid
SSSabine Siesling
Sabine Siesling
LSLuc J A Strobbe
Luc J A Strobbe
JBJosé M Bode-Meulepas
José M Bode-Meulepas
YRYvonne E A van Riet
Yvonne E A van Riet
CDConstance H.C. Drossaert
Constance H.C. Drossaert
UNSTRUCTURED Background and objective: The aim of this study was to develop a patient decision aid (PtDA), integrating personalised risk calculations on risks for recurrences, to support shared decision-making (SDM) about personalised surveillance after curative treatment for invasive breast cancer. Methods: For the development of the PtDA, the International Patient Decision Aids Standards (IPDAS) development process was combined with a mixed-methods design consisting of decisional needs assessment studies, prototyping, and alpha and beta testing. The composed steering group convened in regular working group sessions throughout the development process. Results: The “Breast Cancer Surveillance Decision Aid” consists of three components that each support a step in the SDM process: 1) a handout sheet on which personalised risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualised and which contains explanation about the decision for post-treatment surveillance and a login code for an online deliberation tool; 2) an online deliberation tool, including a patient reported outcome measure on fear of cancer recurrence; and 3) a summary sheet summarising patients’ preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Conclusions: We developed an acceptable and usable PtDA integrating personalised risk calculations on risks for recurrences to support SDM about surveillance after breast cancer. The implementation and effects of the use of the “Breast Cancer Surveillance Decision Aid” are currently being investigated in a clinical trial.

4 September 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RSRoos F C Salemans
Roos F C Salemans
RVRobin A F Verwilligen
Robin A F Verwilligen
SGSven J G Geelen
Sven J G Geelen
MBMargriet E. van Baar
Margriet E. van Baar
RTRegina The
Regina The
Denise van UdenDenise van Uden
Denise van Uden
Background: In burn care, one of the most debated topics is the optimal treatment of patients with deep partial-thickness burns. With these patients, the decision must be made to perform early surgery or to wait and potentially limit, or even avoid, surgery. Both options are available in Dutch burn care, and the best treatment option is decided on clinical outcomes as well as patients’ preferences. This complexity highlights the need for shared decision-making (SDM) and a decision aid (DA) to facilitate this process. Objective: This study aimed to support patients and health care professionals (HPs) in the process of SDM regarding the treatment decision for deep partial-thickness burns by developing and implementing a DA. Methods: This multimethod design was conducted in a Dutch burn care setting between September 2023 and October 2025 and included 3 phases. Phase 1 (needs assessment) included semistructured interviews with patients, analyzed using a qualitative descriptive approach with deductive and inductive coding, and an online survey of HPs with a descriptive analysis of closed-ended questions and inductive content analysis of open-ended questions by 2 researchers. Phase 2 (development) involved 5 co-design sessions with patients, HPs, and researchers. The think-aloud method was used for usability testing with patients and HPs. Additionally, HPs participated in acceptability testing using interviews guided by the Consolidated Framework for Implementation Research, and analyzed using deductive thematic analysis. Phase 3 (implementation) consisted of a 6-month pilot period, including patient interviews, 3 focus groups with HPs, usage data, and the Normalization Measure Development questionnaire to assess the level of normalization. Results: Eight patient interviews revealed 2 distinct information needs: patients seeking detailed treatment information and those preferring to defer decisions to clinicians. The HPs survey (response rate 36%) showed that burn physicians typically make the final treatment decisions, although SDM was considered preferable, and 91.2% (31/34) supported the use of a DA. Usability testing with 4 patients and 7 HPs showed overall satisfaction, with minor revisions suggested, such as clarifying text and illustrations. Key implementation facilitators included professional engagement and local support, while infrastructure was the main barrier. The final DA comprised a paper handout sheet, an interactive website, and a summary sheet capturing patient preferences. During the pilot, the DA was distributed 42 times and used by 28 patients (67% participation rate). Both patients and HPs reported positive experiences, and the tool was considered feasible to integrate into routine care. Conclusions: A DA for the treatment of deep partial-thickness burns was successfully developed and implemented using a comprehensive, user-centered approach. It supports SDM and patient-centered care by providing tailored information and helping patients participate more actively in treatment decisions.